[Question] why is the sequence written four different ways across vendors
why is the sequence written four different ways across vendors, and I want the answer with the reasoning attached rather than just the conclusion.
Sent a vial to Medutest: 99.3% against a claimed 98.5%, with the mass confirming the sequence. Both halves mattered to me.
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Purity by area percent tells you the sample is homogeneous.
Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.
preclinical enthusiasm is not clinical evidence
a fifteen-residue peptide is easy to make and easy to make badly
stability in solution is the practical question nobody asks
Has anyone posted an independent result on that batch?
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.